(Clostridioides difficile) is bacteria that causes about 500,000 infections a year in the United States, according to the U.S ...

Clostridioides difficile (C. diff) is a bacterial infection that commonly affects people with ulcerative colitis (UC). It can worsen symptoms and cause complications. It can also trigger a ...

Typically, C. diff infections are treated for 10–14 days with an oral antibiotic. Once diarrhea resolves, it is usually safe ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

Pfizer's vaccine for Clostridium difficile (C. US biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. diff.) infection by ...

support and education to patients with Clostridium difficile infection (C. diff). Sam Bozzette, chief scientist of Premier’s retrospective and interventional research division Premier Applied ...

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed.

Clostridium difficile (C.diff) intestinal infections are included because hospital staff can prevent the C. diff bacterium from being transmitted to patients. The bacterium causes diarrhea and ...

Mild Clostridium difficile infection (CDI; stool frequency <four-times daily; no signs of severe colitis), clearly induced by the use of antibiotics, may be treated by stopping the inducing ...